• 7270 Citations
  • 36 h-Index
1987 …2024
If you made any changes in Pure these will be visible here soon.

Research Outputs 1987 2019

2019

A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy

Lam, T., McLean, M., Hayden, A., Poljak, A., Cheema, B., Gurney, H., Stone, G., Bahl, N., Reddy, N., Shahidipour, H. & Birzniece, V., 1 May 2019, In : Endocrine Connections. 8, 5, p. 605-615 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Androgens
Urea
Muscles
Liver
Testosterone

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 12 othersBedke, J., Choueiri, T. K., Parnis, F., Khaznadar, T., Thobhani, A., Li, S., Piault-Louis, E., Frantz, G., Huseni, M., Schiff, C., Green, M. C. & Motzer, R. J., 15 Jun 2019, In : The Lancet. 393, 10189, p. 2404-2415 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Randomized Controlled Trials
Disease-Free Survival
Ligands
Research Personnel

Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., Lee, J. L., Vasiliev, A., Miller, W. H., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Bedke, J., Alekseev, B., Wang, J. & 8 othersMariani, M., Robbins, P. B., Chudnovsky, A., Fowst, C., Hariharan, S., Huang, B., Di Pietro, A. & Choueiri, T. K., 21 Mar 2019, In : New England Journal of Medicine. 380, 12, p. 1103-1115 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Disease-Free Survival
sunitinib
avelumab
axitinib
Plasmas
Monitoring
Neoplasms
Drug Monitoring
Castration

Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer

Al-Mansouri, L. & Gurney, H., 16 Jul 2019, In : Asia-Pacific Journal of Clinical Oncology. 8 p.

Research output: Contribution to journalReview articleResearchpeer-review

Castration
Prostatic Neoplasms
docetaxel
Drug Therapy
Taxoids

Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

Al-Mansouri, L., Arasaratnam, M. & Gurney, H., 14 Jun 2019, In : European Journal of Hospital Pharmacy.

Research output: Contribution to journalArticleResearchpeer-review

Prostatic Neoplasms
Survival
Prostate-Specific Antigen
Castration
Alkaline Phosphatase

Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer

Arasaratnam, M., Crumbaker, M., Bhatnagar, A., McKay, M. J., Molloy, M. P. & Gurney, H., Jul 2019, In : Cancer Chemotherapy and Pharmacology. 84, 1, p. 139-146 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Pharmacokinetics
Prostatic Neoplasms
Pharmaceutical Preparations
Chemotherapy
Drug Therapy

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., Porta, C., George, S., Neiman, V., Bracarda, S., Tykodi, S. S., Barthélémy, P., Leibowitz-Amit, R., Plimack, E. R., Oosting, S. F., Redman, B. & 19 othersMelichar, B., Powles, T., Nathan, P., Oudard, S., Pook, D., Choueiri, T. K., Donskov, F., Grimm, M. O., Gurney, H., Heng, D. Y. C., Kollmannsberger, C. K., Harrison, M. R., Tomita, Y., Duran, I., Grünwald, V., McHenry, M. B., Mekan, S., Tannir, N. M. & CheckMate 214 Investigators, 1 Oct 2019, In : The Lancet Oncology. 20, 10, p. 1370-1385 16 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Safety
Therapeutics
Disease-Free Survival
Advisory Committees

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Fradet, Y., Bellmunt, J., Vaughn, D. J., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Nam, K., Frenkl, T. L., Perini, R. F., De Wit, R. & Bajorin, D. F., 1 Jun 2019, In : Annals of Oncology. 30, 6, p. 970-976 7 p., mdz127.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
docetaxel
Paclitaxel
Drug Therapy
Neoplasms
Platinum

Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?

Lee, C. I., Fox, P., Balakrishnar, B., Balleine, R. L., Gao, B., Provan, P., Coulter, S., Liddle, C., Hui, R., Wong, M., Gurney, H. & Wilcken, N., 1 Aug 2019, In : Breast. 46, p. 52-57 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Hot Flashes
Tamoxifen
Cytochrome P-450 CYP2D6
4-hydroxy-N-desmethyltamoxifen
Compliance
2018

Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment

Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. & on behalf of PLATO collaborators, 1 Sep 2018, In : Journal of Clinical Oncology. 36, 25, p. 2639-2646 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Castration
Prostate-Specific Antigen
Prostatic Neoplasms
Prednisone
Control Groups

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews

Van Leeuwen, M. T., Luu, S., Gurney, H., Brown, M. R., Webber, K., Pearson, S-A., Hunt, L. & Vajdic, C. M., 1 Jun 2018, In : BMJ Open. 8, 6, p. 1-6 6 p., e021064.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Ethics
Embolism and Thrombosis
Cerebrovascular Disorders
Neoplasms
Peer Review

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

Gao, B., Lu, Y., Nieuweboer, A. J. M., Xu, H., Beesley, J., Boere, I., De Graan, A. J. M., De Bruijn, P., Gurney, H., Kennedy, C. J., Chiew, Y. E., Johnatty, S. E., Beale, P., Harrison, M., Luccarini, C., Conroy, D., Mathijssen, R. H. J., Harnett, P. R., Balleine, R. L., Chenevix-Trench, G. & 2 othersMacGregor, S. & De Fazio, A., 1 Dec 2018, In : Scientific Reports. 8, 1, p. 1-10 10 p., 1508.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Genome-Wide Association Study
Carboplatin
Paclitaxel
Single Nucleotide Polymorphism
Drug Therapy

Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer

Vaughn, D. J., Bellmunt, J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Li, H., Perini, R. F., Bajorin, D. F. & de Wit, R., 1 Jun 2018, In : Journal of Clinical Oncology. 36, 16, p. 1579-1587 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Quality of Life
Drug Therapy
Neoplasms
Health Status
Research Personnel

Nivolumab in the treatment of advanced renal cell carcinoma

Arasaratnam, M. & Gurney, H., Jul 2018, In : Future Oncology. 14, 17, p. 1679-1689 11 p., 29460635.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Neoplasms
Interleukin-2
Therapeutics
Biomarkers

Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M. O., Bracarda, S. & 13 othersBarrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., Escudier, B. & CheckMate 214 Investigators, 5 Apr 2018, In : New England Journal of Medicine. 378, 14, p. 1277-1290 14 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Disease-Free Survival
Survival
nivolumab
ipilimumab

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

Powles, T., Motzer, R. J., Escudier, B., Pal, S., Kollmannsberger, C., Pikiel, J., Gurney, H., Rha, S. Y., Park, S. H., Geertsen, P. F., Gross-Goupil, M., Grande, E., Suarez, C., Markby, D. W., Arroyo, A., Dean, M., Choueiri, T. K. & George, D., 11 Sep 2018, In : British Journal of Cancer. 119, 6, p. 663-669 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Renal Cell Carcinoma
Disease-Free Survival
Survival
Therapeutics
Everolimus
Plasma (human)
Metabolites
Mass spectrometry
Mass Spectrometry
Pharmaceutical Preparations

Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Crumbaker, M., Guminski, A., Gurney, H., Sabanathan, D., Wong, S. & Pavlakis, N., Apr 2018, In : Asia-Pacific Journal of Clinical Oncology. 14, 2, p. e45-e49 5 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Appointments and Schedules
Therapeutics
sunitinib
Survival
2017

A Distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer

PRIMe Consortium, 15 Nov 2017, In : International Journal of Cancer. 141, 10, p. 2112-2120 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Castration
Prostatic Neoplasms
Lipids
Sphingolipids
Survival

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program

Parente, P., Ng, S., Parnis, F., Guminski, A. & Gurney, H., Dec 2017, In : Asia-Pacific Journal of Clinical Oncology. 13, 6, p. 391-399 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Castration
Prostatic Neoplasms
Quality of Life
Safety
docetaxel

CheckMate 025 randomized Phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma

Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Peltola, K., Wagstaff, J., Gauler, T. C., Ueda, T., Zhao, H., Waxman, I. M., Motzer, R. J. & 1 others CheckMate 025 Investigators, 2017, In : European Urology. 72, 6, p. 962-971 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Outcome Assessment (Health Care)
Survival
Therapeutics
Standard of Care

Communicating risk in active surveillance of localised prostate cancer: A protocol for a qualitative study

Rapport, F., Hogden, A., Gurney, H., Gillatt, D., Bierbaum, M., Shih, P. & Churruca, K., 1 Oct 2017, In : BMJ Open. 7, 10, p. 1-7 7 p., e017372.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Prostatic Neoplasms
Referral and Consultation
Health
Interviews
Communication

Cure in advanced renal cell cancer: Is it an achievable goal?

Sabanathan, D., Park, J. J., Marquez, M., Francisco, L., Byrne, N. & Gurney, H., 1 Dec 2017, In : Oncologist. 22, 12, p. 1470-1477 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Death Domain Receptors
Immunotherapy
Therapeutics
Radiotherapy

Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival

Patel, M. I., Beattie, K., Bang, A., Gurney, H. & Smith, D. P., Oct 2017, In : Cancer Medicine. 6, 10, p. 2188–2193 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Nephrectomy
Renal Cell Carcinoma
Survival
Insurance
South Australia

Dose considerations for anti-cancer drugs in metastatic prostate cancer

Crumbaker, M. & Gurney, H., 1 Aug 2017, In : Prostate. 77, 11, p. 1199-1204 6 p.

Research output: Contribution to journalReview articleResearchpeer-review

docetaxel
Prostatic Neoplasms
Pharmaceutical Preparations
Neoplasms
Quality of Life

Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring

Sabanathan, D., Zhang, A., Fox, P., Coulter, S., Gebski, V., Balakrishnar, B., Chan, M., Liddle, C. & Gurney, H., Aug 2017, In : Cancer Chemotherapy and Pharmacology. 80, 2, p. 385–393 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Drug Monitoring
Renal Cell Carcinoma
Toxicity
Monitoring
Pharmaceutical Preparations

e-TC: development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer

Heiniger, L. E., Smith, A. B., Olver, I., Grimison, P., Klein, B., Wootten, A., Abbott, J-A. M., Price, M. A., McJannett, M., Tran, B., Stockler, M. R., Gurney, H. & Butow, P. N., Nov 2017, In : European Journal of Cancer Care. 26, 6, p. 1-10 10 p., e12698.

Research output: Contribution to journalArticleResearchpeer-review

Testicular Neoplasms
Survivors
Anxiety
Depression
Psychology

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure

Rowland, A., van Dyk, M., Mangoni, A. A., Miners, J. O., McKinnon, R. A., Wiese, M. D., Rowland, A., Kichenadasse, G., Gurney, H. & Sorich, M. J., 2017, In : Expert Opinion on Drug Metabolism and Toxicology. 13, 1, p. 31-49 19 p.

Research output: Contribution to journalReview articleResearchpeer-review

Pharmacokinetics
Phosphotransferases
Expert Testimony
Protein Kinase Inhibitors
Metabolism

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: a Renal Cross Channel Group study

Colomba, E., Le Teuff, G., Eisen, T., Stewart, G. D., Fife, K., Larkin, J., Biondo, A., Pickering, L., Srinivasan, A., Boyle, H., Derosa, L., Sternberg, C. N., Recine, F., Ralph, C., Saldana, C., Barthélémy, P., Bernhard, J. C., Gurney, H., Verhoest, G., Vauleon, E. & 11 othersBigot, P., Berger, J., Pfister, C., Gravis, G., Rodier, J-M., Culine, S., Caty, A., Rolland, F., Priou, F., Escudier, B. & Albiges, L., 1 Jul 2017, In : European Journal of Cancer. 80, p. 55-62 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Sirolimus
Renal Cell Carcinoma
Treatment Failure
Kidney
Confidence Intervals

Pembrolizumab as second-line therapy for advanced urothelial carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Poehlein, C. H., Perini, R. F. & Bajorin, D. F., 16 Mar 2017, In : New England Journal of Medicine. 376, 11, p. 1015-1026 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Confidence Intervals
Carcinoma
Drug Therapy
Platinum
Neoplasms

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer

Lin, H-M., Mahon, K. L., Spielman, C., Gurney, H., Mallesara, G., Stockler, M. R., Bastick, P., Briscoe, K., Marx, G., Swarbrick, A. & Horvath, L. G., 11 Apr 2017, In : British Journal of Cancer. 116, 8, p. 1002-1011 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Castration
MicroRNAs
docetaxel
Prostatic Neoplasms
Biomarkers

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S. & Sorich, M. J., 26 Sep 2017, In : British Journal of Cancer. 117, 7, p. 913-920 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Biomarkers
Therapeutics
Leukocyte Count
Research
C-Reactive Protein

Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025

Escudier, B., Motzer, R. J., Sharma, P., Wagstaff, J., Plimack, E. R., Hammers, H. J., Donskov, F., Gurney, H., Sosman, J. A., Zalewski, P. G., Harmenberg, U., McDermott, D. F., Choueiri, T. K., Richardet, M., Tomita, Y., Ravaud, A., Doan, J., Zhao, H., Hardy, H. & George, S., Sep 2017, In : European Urology. 72, 3, p. 368-376 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Therapeutics
Karnofsky Performance Status
Response Evaluation Criteria in Solid Tumors
nivolumab
2016

Case series: silent malignant spinal cord compression (MSCC) secondary to spinal epidural metastases (SEM) in castrate-resistant prostate cancer (CRPC)

Park, J., Sabanathan, D., Lau, A. & Gurney, H., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S4, p. 66-66 1 p.

Research output: Contribution to journalMeeting abstractResearch

Case series: silent malignant spinal cord compression (MSCC) secondary to spinal epidural metastases (SEM) in castrate-resistant prostate cancer (CRPC)

Park, J. J., Sabanathan, D., Lau, A. & Gurney, H., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S3, p. 38-38 1 p.

Research output: Contribution to journalMeeting abstractResearch

Differences in the patterns of anti-pd1 (PD1) toxicity between tumor streams

Sabanathan, D., Kong, B., Byrne, N., Wegener, V., Eslick, G., Nagrial, A., Hui, R., Kefford, R., Gurney, H. & Carlino, M. S., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S4, p. 68-68 1 p.

Research output: Contribution to journalMeeting abstractResearch

Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE study

Fox, P., Balleine, R. L., Lee, C., Gao, B., Balakrishnar, B., Menzies, A. M., Yeap, S. H., Ali, S. S., Gebski, V., Provan, P., Coulter, S., Liddle, C., Hui, R., Kefford, R., Lynch, J., Wong, M., Wilcken, N. & Gurney, H., 1 Jul 2016, In : Clinical Cancer Research. 22, 13, p. 3164-3171 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Drug Monitoring
Tamoxifen
Hot Flashes
Cytochrome P-450 CYP2D6
Genotype

High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation

Nath, C. E., Trotman, J., Tiley, C., Presgrave, P., Joshua, D., Kerridge, I., Kwan, Y. L., Gurney, H., McLachlan, A. J., Earl, J. W., Nivison-Smith, I., Zeng, L. & Shaw, P. J., Jul 2016, In : British Journal of Clinical Pharmacology. 82, 1, p. 149-159 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Melphalan
Autologous Transplantation
Area Under Curve
Survival
Stem Cell Transplantation

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Lawrence, N., Martin, A., Toner, G., Stockler, M., Buizen, L., Thomson, D., Gebski, V., Friedlander, M., Yeung, A., Wong, N., Gurney, H., Rosenthal, M., Singhal, N., Kichenadasse, G., Wong, S., Lewis, C., Vasey, P. & Grimison, P., 1 Dec 2016, In : Annals of oncology : official journal of the European Society for Medical Oncology. 27, 12, p. 2302-2303 2 p.

Research output: Contribution to journalLetterResearchpeer-review

MILGa-01-a first in human study assessing the safety and tolerability of chMIL-38 in prostate cancer

Sabanathan, D., Gurney, H., Gillatt, D., Trifunovic, M., Magnussen, J., Poursoltan, P., Shon, K. H. O., Walsh, B. J., Mazure, H., Velonas, V., Thurecht, K., Quach Truong, Wissmueller, S. & Campbell, D., Aug 2016, In : BJU international. 118, Suppl. 1, p. 14-15 2 p.

Research output: Contribution to journalMeeting abstractResearch

Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011

van Leeuwen, M. T., Gurney, H., Turner, J. J., Turner, S. L., Pearson, S. A., Laaksonen, M. A., Harnett, P., Balakrishnar, B., Sabanathan, D. & Vajdic, C. M., 1 Aug 2016, In : Cancer Epidemiology. 43, p. 15-21 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Germ Cell and Embryonal Neoplasms
Pediatrics
Incidence
Neoplasms
Germinoma

Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Crumbaker, M., Gurney, H., Guminski, A., Wong, S., Sabanathan, D. & Pavlakis, N., Jul 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, S3, p. 47 1 p., abs#209.

Research output: Contribution to journalMeeting abstractResearch

Tactic: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

Ferraro, D., Goldstein, D., O’Connell, R. L., Zalcberg, J. R., Sjoquist, K. M., Tebbutt, N. C., Grimison, P., McLachlan, S., Lipton, L. L., Vasey, P., Gebski, V. J., Aiken, C., Cronk, M., Ng, S., Karapetis, C. S., Shannon, J., Shannon, J., Tebbutt, N., Ng, S., Cronk, M. & 48 othersKarapetis, C., Sjoquist, K., Aiken, C., Do, V., Marschner, I., Friedlander, M., Gurney, H., Simes, J., Hague, W., O’Connell, R., Gebski, V., Aiken, C., Gorzeman, M., Pike, R., Miranda, K., Waring, P., Ferraro, D., Lau, D., Fox, S., Tebbutt, N., Liu, Y., Vasey, P., Wood, T., Cronk, M., Cocks, C., Simmons, K., Shannon, J., McCourt, J., Jefford, M., Hobinchet, A., Grimison, P., Mirco, B., Sagong, J., Ng, S., Dudukovic, S., Aghmesheh, M., Parker, S., Segelov, E., Ratnayake, L., McLachlan, S., Ranieri, N., Varma, S., Page, J., Heyer, E., Abdi, E., Chorlton, C., Lipton, L. & Wilkinson, L., 1 Aug 2016, In : Cancer Chemotherapy and Pharmacology. 78, 2, p. 361-367 7 p.

Research output: Contribution to journalArticleResearchpeer-review

gemcitabine
Biliary Tract Neoplasms
Cisplatin
Toxicity
Labels

Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections

Lee, C. I. & Gurney, H., 1 Nov 2016, In : Cancer Forum. 40, 3, p. 4-10 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Cytochrome P-450 CYP2D6
Tamoxifen
Hormones
Breast Neoplasms
Selective Estrogen Receptor Modulators

The effect of pulmonary function testing on bleomycin dosing in germ cell tumours

Roncolato, F. T., Chatfield, M., Houghton, B., Toner, G., Stockler, M., Thomson, D., Friedlander, M., Gurney, H., Rosenthal, M., Grimison, P. & The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP), 1 Aug 2016, In : Internal Medicine Journal. 46, 8, p. 893-898 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Germ Cell and Embryonal Neoplasms
Bleomycin
Lung
Vital Capacity
Lung Volume Measurements

The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study

Smith, A. B., Butow, P., Olver, I., Luckett, T., Grimison, P., Toner, G. C., Stockler, M. R., Hovey, E., Stubbs, J., Turner, S., Hruby, G., Gurney, H., Alam, M., Cox, K. & King, M. T., 1 Apr 2016, In : Journal of Cancer Survivorship. 10, 2, p. 223-233 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Testicular Neoplasms
Survival Rate
Quality of Life
Psychology
Survivors
2015

CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

Sharma, P., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Xu, L. A., Waxman, I. M. & Motzer, R. J., Sep 2015, In : European Journal of Cancer. 51, Supplement 3, p. S708 1 p.

Research output: Contribution to journalMeeting abstractResearch

CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)

Motzer, R. J., Escudier, B., Mcdermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Xu, L-A., Waxman, I. M., Sharma, P. & 1 others CheckMate 025 Investigators, Dec 2015, In : BJU international. 116, S5, p. 17 1 p.

Research output: Contribution to journalMeeting abstractResearch